| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | JQ-1 | GDSC1000 | pan-cancer | AAC | 0.059 | 0.07 |
| mRNA | YK 4-279 | GDSC1000 | pan-cancer | AAC | 0.065 | 0.07 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | 0.11 | 0.07 |
| mRNA | IPA-3 | GDSC1000 | pan-cancer | AAC | 0.059 | 0.07 |
| mRNA | temsirolimus | CTRPv2 | pan-cancer | AAC | -0.086 | 0.07 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | 0.065 | 0.08 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.066 | 0.08 |
| mRNA | skepinone-L | CTRPv2 | pan-cancer | AAC | -0.092 | 0.08 |
| mRNA | paclitaxel | UHNBreast | pan-cancer | AAC | 0.53 | 0.08 |
| mRNA | KIN001-055 | GDSC1000 | pan-cancer | AAC | 0.06 | 0.08 |